Leishmaniasis Treatment Market Analysis & Forecast: 2026-2033

Leishmaniasis Treatment Market Size and Share Analysis - 2026 To 2033

The Leishmaniasis treatment market is anticipated to grow at a CAGR of 10.58% with USD 170 Mn in 2026 and is expected to reach USD 340 Mn in 2033. The leishmaniasis treatment market is expected to grow in the coming years due to large healthcare spending (In 2024, healthcare spending is estimated to account for 9.3% of GDP on average), improved healthcare infrastructure, and increasing efforts to control infectious diseases. Greater awareness, better diagnosis, as well as improved access to treatment options are also supporting market growth, especially in regions where leishmaniasis is more common.

Key Takeaways

• Cutaneous leishmaniasis segment is expected to account the largest share of 55.0% in 2026, Cutaneous leishmaniasis is the most common form of leishmaniasis globally, with an estimated 600,000 in 1 Mn new cases annually. It affects skin as well as causes ulcers/scarring, creating a large treatment demand.
• Pentavalent antimonials segment will dominate with 60.0% in 2026, Pentavalent antimonials were the first widely adopted systemic medicines for leishmaniasis and became embedded in national treatment programs. Cure rates remain high in areas where antimony resistance is low. Pentavalent antimonials can cure about 90–97% of patients after one to three full intravenous treatment courses.
• Asia Pacific is expected to acquire the dominant share of 35.00% in 2026, because of its historically high visceral leishmaniasis burden, large treated population, and established public-health treatment programs. India contributes around 18% of global kala-azar cases. Bihar, Jharkhand, Uttar Pradesh, and West Bengal have the highest number of cases.

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Cutaneous Leishmaniasis Segment Acquiring the Largest Market Share?

Cutaneous Leishmaniasis segment is projected to account for the largest share of disease type in 2026, representing approximately 55.0% of the total volume. Cutaneous Leishmaniasis (CL) stands as the most common form of leishmaniasis globally, having the largest proportion of reported cases year after year. According to the World Health Organization (WHO), as of July 2026, 62 countries where visceral leishmaniasis (VL) is common and 61 countries where cutaneous leishmaniasis (CL) is common reported disease data for 2024 in the WHO Global Leishmaniasis Programme.

According to the World Health Organization (WHO), cutaneous leishmaniasis represents approximately 95% of all new leishmaniasis cases globally, with hundreds of thousands of new cases documented annually. This staggering disease burden naturally translates into the highest demand for treatment products, diagnostic tools, as well as therapeutic protocols, making it the leading segment in the market.

The disease manifests as skin lesions, ulcers, nodules, etc., primarily on exposed areas of the body, and while it is rarely fatal, the chronic nature of infection, prolonged healing times, as well as risk of secondary infections necessitate long-term pharmacological management, further amplifying treatment demand.

Pentavalent Antimonials Segment holds the Largest Market Share 

To learn more about this report, Request Free Sample

Based on drug type, Pentavalent Antimonials segments dominates the market, accounting for a significant 60.0% share in 2026. Pentavalent Antimonials, which include compounds such as sodium stibogluconate (Pentostam) as well as meglumine antimoniate (Glucantime), have maintained their dominant position in the Leishmaniasis treatment market for many decades now.

Their dominance is attributed to their well-documented therapeutic history, high regulatory acceptance, as well as inclusion in essential medicine lists across numerous endemic countries.

The World Health Organization (WHO) has consistently included pentavalent antimonials in its recommended treatment guidelines for visceral, cutaneous, as well as mucocutaneous leishmaniasis, which has significantly reinforced their adoption across low- and middle-income countries where the disease burden is highest.

According to WHO, leishmaniasis is endemic in more than 90 countries, and pentavalent antimonials remain the frontline treatment option in a large proportion of these regions, particularly in parts of South Asia, Latin America, East Africa, and the Middle East.

Market Drivers

Liposomal Drug Delivery Technology: A major breakthrough in Leishmaniasis Treatment

Liposomal drug delivery technology uses tiny fat-based particles called liposomes to carry Amphotericin B directly to infected cells. This technology improves drug delivery by targeting macrophages (immune cells where Leishmania parasites live), increasing circulation time, reducing kidney toxicity by about 10 times compared with conventional Amphotericin B, as well as allowing effective single-dose treatment for visceral leishmaniasis.

Companies using this technology include Gilead Sciences (AmBisome), Bharat Serums and Vaccines (Fungisome), and Sun Pharma (Amphomul). AmBisome, originally developed for fungal infections, later received WHO prequalification for visceral leishmaniasis treatment. Through partnerships with WHO, Médecins Sans Frontières (MSF), and DNDi, Gilead helped reduce the price of AmBisome to around $18 per vial for developing countries compared with USD400+ in developed markets, supporting wider access to WHO-recommended single-dose therapy (10 mg/kg).

Current Events and Their Impact on the Leishmaniasis Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Leishmaniasis Treatment Market Trends

• The market is experiencing a change from traditional intravenous and intramuscular formulations notably Amphotericin B and pentavalent antimonials toward oral therapies such as Miltefosine, which provide superior patient compliance and reduced hospitalization requirements. Miltefosine has shown a cure rate of more than 95% in treating leishmaniasis, making it an effective oral treatment.
• Multilateral organizations including the World Health Organization (WHO), Médecins Sans Frontières (MSF), Bill & Melinda Gates Foundation, the Wellcome Trust, etc., are channeling substantial funds into research, drug development pipelines, as well as treatment access programs.
• The treatment pipeline is highly diverse, with investigational compounds such as LXE408 (Novartis), GSK3494245, as well as several repurposed molecules entering clinical trials. Immunotherapeutic approaches as well as vaccine candidates (e.g., LEISH-F3+GLA-SE, ChAd63-KH) are gaining traction as preventive and adjunct therapeutic modalities, promising to redefine long-term market dynamics.
• Rapid diagnostic tests (RDTs), including the rK39 immunochromatographic test for VL, are being highly integrated into national health programs, enabling earlier, more accurate diagnosis and consequently improving treatment penetration rates.

Regional Insights 

To learn more about this report, Request Free Sample

Asia Pacific dominates owing to its overwhelming burden of visceral leishmaniasis (VL)

Asia Pacific account 35.00% market share in 2026, owing to its overwhelming burden of visceral leishmaniasis (VL), also known as kala-azar, concentrated across the Indian subcontinent, Bangladesh, and Nepal. South-East Asia accounted for about 67% of the world’s kala-azar (KA) cases in 2006, but this share dropped to only 6% in 2023. In India, kala-azar cases decreased significantly from 77,102 cases in 1992 to much lower levels in recent years due to improved disease control and treatment programs.

The World Health Organization (WHO) has consistently identified the South-East Asia Region as one of the most endemic zones globally, with India alone accounting for a disproportionately large share of global VL cases.

The National Vector Borne Disease Control Programme (NVBDCP) of the government authorities of India has been fundamental in rolling out treatment access through first-line drugs including miltefosine, liposomal amphotericin B, etc., driving consistent demand for therapeutic products.

Furthermore, the Kala-Azar Elimination Programme, which focus on interruption of transmission in endemic states like Bihar, Jharkhand, Uttar Pradesh, West Bengal, etc., has structured a robust public health procurement framework that sustains treatment volumes.

North America Leishmaniasis Treatment Market Trends

The North America region is poised to be the fastest-growing region through 2026-2033, expanding at a CAGR of approximately 7.2%. The region is driven by an accelerating recognition of autochthonous transmission risks, expanded domestic surveillance programs, as well as a growing population of immunocompromised patients susceptible to Leishmania infections. Recent estimates show that around 6.6% of the U.S. population is immunocompromised, representing more than 20 million people.

The United States Centers for Disease Control and Prevention (CDC) has increasingly documented locally acquired cutaneous leishmaniasis cases in southern states, particularly Texas, where the sand fly vector Lutzomyia anthophora has been identified as a competent transmission vector.

This domestic transmission reality has prompted federal health agencies to reassess leishmaniasis as not merely a neglected tropical disease affecting travelers and immigrants but as an emerging domestic public health concern.

Robust National Disease Surveillance Infrastructure is Accelerating the Leishmaniasis Treatment Market Demand in China

China contributes the highest share in the market in Asia Pacific owing to its robust national disease surveillance infrastructure, extensive public health investment, and well-established pharmaceutical manufacturing capabilities that collectively position it as the dominant force within the regional Leishmaniasis treatment landscape.

China has historically catered visceral leishmaniasis, locally known as Kala-azar, particularly across its northwestern provinces including Gansu, Sichuan, Shaanxi, as well as Xinjiang, where the disease remains endemic. The Chinese Center for Disease Control and Prevention (China CDC) has maintained active reporting as well as vector control programs targeting Phlebotomus chinensis, the primary sandfly vector responsible for disease transmission in these regions.

According to a report by the World Health Organization, China has eliminated systematic treatment protocols utilizing Sodium Stibogluconate and Miltefosine as first-line therapeutic agents, with government-subsidized treatment access under its national rural cooperative medical scheme making sure high population coverage.

U.S. Leishmaniasis Treatment Market Trends

The U.S. contributes the highest share in the market in North America owing to its well-established healthcare infrastructure, robust pharmaceutical research ecosystem, and significant federal investment in neglected tropical disease (NTD) programs.

The United States has historically maintained a strong institutional response to leishmaniasis, particularly given its military engagement in endemic regions such as the Middle East as well as Central Asia, where American troops have been disproportionately exposed to cutaneous leishmaniasis.

According to the U.S. Centers for Disease Control and Prevention (CDC), cases of leishmaniasis reported in the United States predominantly affect returning travelers, immigrants from endemic countries, as well as the U.S. military personnel, with the CDC's Division of Parasitic Diseases actively maintaining surveillance as well as treatment protocols for the disease.

The U.S. Food and Drug Administration (FDA) has approved miltefosine marketed as Impavido specifically for the treatment of leishmaniasis in the United States, representing one of the very few approved oral therapies available in a high-income country, which substantially reinforces the country's treatment market position.

Who are the Major Companies in Leishmaniasis Treatment Industry

Some of the major key players in Leishmaniasis treatment market include, Sanofi S.A., Sequus Pharmaceuticals Inc., Paladin Labs Inc., Enzon Pharmaceuticals Inc., Gland Pharma Limited, and Lifecare Innovations Private Limited.

Key News

• In May 2026, Gilead Sciences has renewed its five-year partnership with the World Health Organization (WHO) to support the elimination of visceral leishmaniasis (VL), also known as kala-azar. The company will provide funding, strategic support, and medicine donations to help control the disease. VL is a serious parasitic infection spread by sandflies that affects internal organs and can be fatal if not treated.
• In July 2026, the non-profit research organization Drugs for Neglected Diseases initiative (DNDi) has received about JPY 778 million (around EUR 4.2 million) in funding from the Global Health Innovative Technology (GHIT) Fund to support the development of DNDI-6174, a new treatment candidate for neglected diseases. The project is being developed in collaboration with Eisai Co., Ltd.

Market Report Scope 

Analyst Opinion

• Leishmaniasis remains one of the most neglected tropical diseases globally, predominantly affecting populations in low-to-middle-income countries across South Asia, East Africa, and Latin America. More than 350 million people are at risk of having CL or MCL in over 98 endemic countries.
• The market for leishmaniasis treatment is driven by high disease burden, growing awareness initiatives by international health organizations such as the WHO, as well as sustained funding from governmental and non-governmental bodies targeting neglected tropical diseases.
• Predominance of visceral leishmaniasis, in endemic regions, continues to make high demand for effective therapeutic interventions.
• However, the market faces restraints, including limited commercial attractiveness due to the saturated disease burden in economically disadvantaged populations, which discourages private pharmaceutical investment.
• On the opportunity front, increased public-private partnerships as well as orphan drug designations are encouraging pharmaceutical companies to develop novel treatment candidates with improved safety and efficacy profiles.

Market Segmentation

• By Disease Type (Revenue, USD Mn, 2021-2033)
  • Cutaneous leishmaniasis
  • Visceral leishmaniasis
  • Mucocutaneous leishmaniasis
• By Drug Type (Revenue, USD Mn, 2021-2033)
  • Pentavalent antimonials
    • Sodium stibogluconate
    • SSG Meglumine antimoniate
  • Antibiotics
    • Amphotericin B
    • Liposomal amphotericin B
    • Miltefosine
    • Paromomycin
    • Pentamidine
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Infectious Disease Specialists & Parasitologists
• Pharmaceutical & Biotechnology Companies (Manufacturing Leishmaniasis Drugs)
• Hospital Pharmacists & Clinical Researchers
• Public Health Officials & Epidemiologists
• Others

Databases

• World Health Organization (WHO) Global Health Observatory Database
• ClinicalTrials.gov Database
• IQVIA Pharma Intelligence Database
• Global Burden of Disease (GBD) Database
• Others

Magazines

• Pharmaceutical Technology Magazine
• Drug Discovery & Development Magazine
• Infectious Disease Advisor Magazine
• BioPharmaceutical International Magazine
• Others

Journals

• PLOS Neglected Tropical Diseases Journal
• The Lancet Infectious Diseases Journal
• American Journal of Tropical Medicine and Hygiene
• Journal of Antimicrobial Chemotherapy
• Others

Newspapers

• The BMJ (British Medical Journal News)
• STAT News (Health & Pharma News)
• Reuters Health News
• Fierce Pharma News
• Others

Associations

• World Health Organization (WHO) – Neglected Tropical Diseases Division
• Drugs for Neglected Diseases Initiative (DNDi)
• Leishmaniasis East Africa Platform (LEAP)
• International Society of Infectious Diseases (ISID)
• Others

Public Domain Sources

• WHO Leishmaniasis Fact Sheets & Reports
• U.S. Centers for Disease Control and Prevention (CDC) – Parasitic Diseases Data
• U.S. Food and Drug Administration (FDA) – Drug Approval Databases
• European Medicines Agency (EMA) – Public Assessment Reports
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years